- Conditions
- Anemia
- Interventions
- Short storage RBC age
- Biological
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 3 Days to 15 Years
- Enrollment
- 1,538 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 865–888
of 17,848
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma
- Interventions
- Cisplatin, IMRT 6 weeks, IMRT 5 weeks
- Drug · Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 207
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 168 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- XL184, erlotinib
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 13
- States / cities
- Anchorage, Alaska • Palo Alto, California • Sacramento, California + 9 more
- Conditions
- HIV Infections
- Interventions
- Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF), Cabotegravir (CAB), Lenacapavir Tablet
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Timeline
- 2026 – 2029
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 29 more
- Conditions
- Prostate Cancer
- Interventions
- PROSTVAC®-VF/TRICOM™
- Biological
- Lead sponsor
- Bavarian Nordic
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 47
- States / cities
- Homewood, Alabama • Anchorage, Alaska • Fresno, California + 41 more
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- MMFS-202-302, Placebo
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Osteoarthritis, Knee, Pain, Nerve; Lesion
- Interventions
- genicular nerve diagnostic block with lidocaine (local anesthetic), genicular nerve radiofrequency ablation
- Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Diabetes Mellitus, Type 2, Acute Coronary Syndrome
- Interventions
- Alogliptin, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 292
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 289 more
- Conditions
- Sickle Cell Anemia
- Interventions
- Not listed
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 8 Years to 21 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Lymphoma
- Interventions
- Rituximab, Cytarabine, Dexamethasone, Leucovorin, Methotrexate, Procarbazine, Vincristine
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 68
- States / cities
- Stanford, California • Gainesville, Florida • Jacksonville, Florida + 51 more
- Conditions
- Ileus
- Interventions
- ElectroCore RMS-1100 Resolution Motility System™
- Device
- Lead sponsor
- ElectroCore INC
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Philadelphia, Pennsylvania
- Conditions
- Pain Associated With Osteoarthritis of the Knee
- Interventions
- X0002
- Drug
- Lead sponsor
- Techfields Pharma Co. Ltd
- Industry
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 399 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Yuma, Arizona • Anaheim, California + 29 more
- Conditions
- Acute Ischemic Stroke, Thrombotic Disease
- Interventions
- DS-1040b, Placebo
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 16
- States / cities
- Mobile, Alabama • Los Angeles, California • Colorado Springs, Colorado + 13 more
- Conditions
- OSA
- Interventions
- AD109, Placebo
- Drug
- Lead sponsor
- Apnimed
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Little Rock, Arkansas + 59 more
- Conditions
- Minor Surgical Procedures With Monitored Anesthesia Care, Driving Performance After Minor Ambulatory Surgery
- Interventions
- Midazolam, Sufentanil, Propofol
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 625 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Crohn's Disease (CD)
- Interventions
- Risankizumab, Ustekinumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 527 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 72
- States / cities
- Chandler, Arizona • Coronado, California • Irvine, California + 62 more
- Conditions
- Cancer Survivor, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma
- Interventions
- Afimoxifene, Core Biopsy, Questionnaire Administration
- Drug · Procedure · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Diffuse Intrinsic Pontine Glioma, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Primary Central Nervous System Neoplasm
- Interventions
- Biospecimen Collection, Magnetic Resonance Imaging, Savolitinib, X-Ray Imaging
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 6 Years to 21 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more
- Conditions
- Atopic Dermatitis
- Interventions
- Upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 475 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 33
- States / cities
- Little Rock, Arkansas • Fountain Valley, California • Fresno, California + 27 more
- Conditions
- Alzheimer Disease
- Interventions
- Investigational drug
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2005
- U.S. locations
- 34
- States / cities
- Peoria, Arizona • Beverly Hills, California • Los Alamitos, California + 29 more
- Conditions
- Major Depressive Disorder
- Interventions
- mixed salts amphetamine
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Interventions
- Biospecimen Collection, Diagnostic Imaging Testing, Excisional Biopsy, Indocyanine Green Solution, Minimally Invasive Surgery, Pelvic Lymphadenectomy, Questionnaire Administration, Sentinel Lymph Node Mapping
- Procedure · Drug · Other
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 428 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 55
- States / cities
- Washington D.C., District of Columbia • Coral Gables, Florida • Deerfield Beach, Florida + 41 more
- Conditions
- Healthy
- Interventions
- MEDI-559, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 1 Month to 23 Months
- Enrollment
- 116 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 75
- States / cities
- Greenville, Alabama • Huntsville, Alabama • Mobile, Alabama + 62 more
- Conditions
- Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
- Interventions
- AZD0120, SOC
- Biological · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 12
- States / cities
- Tucson, Arizona • Duarte, California • Stanford, California + 8 more